Correlation between Serum Dehydroepiandrosterone Sulfate and LDL Cholesterol in Patients with Polycystic Ovarian Syndrome
DOI:
https://doi.org/10.24293/ijcpml.v27i1.1600Keywords:
Dehydroepiandrosterone sulfate, low-density lipoprotein cholesterol, polycystic ovarian syndromeAbstract
Polycystic Ovary Syndrome (PCOS) is the most prevalent endocrine disorder in female of childbearing age. PCOS patients also have metabolic and cardiovascular disorder risks. One of the factors that can affect those disorders is androgen hormone level. Dehydroepiandrosterone, is produced by the adrenal gland, and its metabolite dehydroepiandrosterone sulphate (DHEAS) has a different effect than testosterone. DHEA and DHEAS might have a protective effect to dyslipidemia and cardiovascular disorder. LDL cholesterol is an important parameter for dyslipidemia therapy guide according to The National Cholesterol Education Program Adult Treatment Panel. The aim of this study was to analyze the correlation between DHEAS and LDL cholesterol. This research was a cross sectional observational study. DHEAS and LDL cholesterol were examined in 25 research subjects by chemiluminescent immunoassay (Immulite®, Siemens) and colorimetric enzymatic (Dimension EXL®, Siemens). These subjects were divided into 3 groups according to 2003 Rotterdam's criteria. Spearman and Pearson's correlation statistical analysis were done, with a significance of p-value less than 0.05 This study showed a moderate negative correlation between DHEAS and LDL cholesterol (r= -0.441, p = 0.027). Group D PCOS (non-hyperandrogenic) had a strong negative correlation between DHEAS and LDL cholesterol (r=-0.717, p= 0.001). DHEA, in some literatures was shown to activate Peroxisome Proliferator Activated Response γ (PPAR γ) receptors and thereby increasing LDL-cholesterol receptors in adipose tissue and LDL-cholesterol uptake from serum. The rise in DHEAS might indicate a better prognosis for PCOS patients in terms of cardiovascular complications, especially in group D PCOS.
Downloads
References
Santoso B. Sindroma ovarium polikistik: Problem reproduksi dan tantangannya terkait gaya hidup. Unair repository. Surabaya, Airlangga University Press, 2020. http://repository.unair.ac.id/40072/1/
gdlhub-gdl-grey-2016-santosobud-40453-pg.12-14-s.pdf (accessed 14 December, 2019).
Cussons AJ, Watts GF, Burke V, Shaw JE, Zimmet PZ, Stuckey B. Cardiometabolic risk in polycystic ovary
syndrome: A comparison of different approaches to defining the metabolic syndrome. Human
Reproduction, 2008; 23(10): 2352-2358.
Rizzo M. Long-term consequences of polycystic ovary syndrome on cardiovascular risk. Fertility and Sterility, 2009; 91(4): 1563-1567.
Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: Systematic review and meta-analysis. Fertility and Sterility, 2011; 95(3): 1073-1079.
C h r i s t o d o u l a k i C , P e r g i a l i o t i s V . Dehydroepiandrosterone-sulfate, insulin resistance,
and ovarian volume estimation in patients with polycystic ovarian syndrome. Journal of Family and
Reproductive Health, 2017; 11(1): 24-29.
KöÅŸüÅŸ N, KöÅŸüÅŸ A, Kamalak Z, Hizli D, Turhan Ní–. Impact of adrenal versus ovarian androgen ratio on signs and symptoms of polycystic ovarian syndrome. Gynecological Endocrinology, 2012; 28(8): 611-614.
Simoncini T, Mannella P, Fornari L, Varone G, Caruso A, et al. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology, 2003; 144(8): 3449-3455.
Mannic T, Viguie J, Rossier MF. In-vivo and in-vitro evidences of dehydroepiandrosterone protective role on the cardiovascular system. International Journal of Endocrinology and Metabolism, 2015; 13(2): 1-5.
Chen M, Chen C, Yang J, Chen C, Ho H, et al. High serum dehydroepiandrosterone sulfate is associated
with phenotypic acne and a reduced risk of abdominal obesity in women with polycystic ovary syndrome. Hum. Reprod, 2011; 26: 219-220.
Brennan K, Huang A, Azziz R. Dehydroepiandrosterone sulfate and insulin resistance in patients with
polycystic ovary syndrome. Fertility and Sterility, 2009; 91(5): 1848-1852.
Grundy S, Berker D, Clark L, Cooper R. Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). NIH Publication, 2002; 2: 3-4.
Wiweko B, Indra I, Susanto C, Natadisastra M, Hestiantoro A. The correlation between serum AMH
and HOMA IR among PCOS phenotypes. BMC Research Notes, 2018; 1: 1-6.
Huang Z, Yong E. Ethnic differences: Is there an Asian phenotype for polycystic ovarian syndrome?. Best Practice & Research Clinical Obstetrics & Gynaecology, 2016; 2: 1-28.
Rojas J, Chávez M, Olivar L, Rojas M, Morillo J, et al. Polycystic ovary syndrome, insulin resistance, and
obesity: Navigating the pathophysiologic labyrinth. International Journal of Reproductive Medicine, 2014; 14: 1-17.
Sachdeva G, Gainder S, Suri V, Sachdeva N, Chopra S. Comparison of the different PCOS phenotypes based on clinical metabolic, and hormonal profile, and their response to clomiphene. Indian J Endocr and Metab, 2019; 23: 326-331.
Chui, PC, Guan H, Lehrke M, Lazar MA. PPAR regulates adipocyte cholesterol metabolism via
oxidized LDL receptor 1. Journal of Clinical Investigation, 2005; 115(8): 2244-2256.
Hennings C, Kurzman I, Haffa A, Kemnitz J, Macewen E. The effect of high-fat diet and
dehydroepiandrosterone (DHEA) administration in the rhesus monkey. In-Vivo, 1995; 5: 415-420.
Lasco A, Frisina N, Morabito N, Gaudio A, Morini E, et al. Metabolic effects of dehydroepiandrosterone replacement therapy in post-menopausal women. European Journal of Endocrinology, 2001; 145: 457-461.
Lerchbaum E, Schwetz V, Giuliani A, Pieber TR. Opposing effects of dehydroepiandrosterone sulfate
and free testosterone on metabolic phenotype in women with polycystic ovary syndrome. Fertility and
Sterility, 2012; 98(5): 1318-1325.e1.
Gambineri A, Vicennati V, Genghini S, Tomassoni F, Pagotto U, et al. Genetic variation in 11
B-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with
polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 2006; 91(6): 2295-23.
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
